A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific Hit
Open Access
- 19 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Neglected Tropical Diseases
- Vol. 5 (7), e1253
- https://doi.org/10.1371/journal.pntd.0001253
Abstract
The ability to screen compounds in a high-throughput manner is essential in the process of small molecule drug discovery. Critical to the success of screening strategies is the proper design of the assay, often implying a compromise between ease/speed and a biologically relevant setting. Leishmaniasis is a major neglected disease with limited therapeutic options. In order to streamline efforts for the design of productive drug screens against Leishmania, we compared the efficiency of two screening methods, one targeting the free living and easily cultured promastigote (insect–infective) stage, the other targeting the clinically relevant but more difficult to culture intra-macrophage amastigote (mammal-infective) stage. Screening of a 909-member library of bioactive compounds against Leishmania donovani revealed 59 hits in the promastigote primary screen and 27 in the intracellular amastigote screen, with 26 hits shared by both screens. This suggested that screening against the promastigote stage, although more suitable for automation, fails to identify all active compounds and leads to numerous false positive hits. Of particular interest was the identification of one compound specific to the infective amastigote stage of the parasite. This compound affects intracellular but not axenic parasites, suggesting a host cell-dependent mechanism of action, opening new avenues for anti-leishmanial chemotherapy. Leishmaniasis, a disease caused by protozoan parasites of the genus Leishmania, is a poverty-related disease threatening 350 million people throughout the world. Drugs currently available to treat this disease are toxic to the patient and drug-resistant parasites are emerging. New therapeutics are therefore needed. Fortunately, interest in confronting the treatment challenges has grown and new technology has led to an increase in high-throughput screens conducted against Leishmania. In order to gain insight into the most efficient screening strategy, we compared two methods, one targeting the easily cultured insect-infective promastigote stage of the parasite, and the other, targeting the clinically relevant but more difficult to culture intracellular amastigote stage. We show that while a screen against promastigotes is amenable to automation, it fails to recognize all active compounds. These compounds revealed only by an intracellular assay might act on host cell pathways important for parasite development. Targeting such pathways is an emerging strategy in drug discovery against infectious diseases.Keywords
This publication has 47 references indexed in Scilit:
- Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasisBiochemical Pharmacology, 2010
- Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi , the Agent of Chagas' DiseaseAntimicrobial Agents and Chemotherapy, 2010
- Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New ScaffoldsPLoS Neglected Tropical Diseases, 2010
- Identification of Host-Dependent Survival Factors for Intracellular Mycobacterium tuberculosis through an siRNA ScreenPLoS Pathogens, 2010
- Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule ScreenPLoS Neglected Tropical Diseases, 2009
- In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific DifferencesAntimicrobial Agents and Chemotherapy, 2009
- Host-Directed Drug Targeting of Factors Hijacked by PathogensScience Signaling, 2008
- The Genome Sequence of Trypanosoma cruzi , Etiologic Agent of Chagas DiseaseScience, 2005
- Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide releaseInternational Journal of Immunopharmacology, 1995
- Naloxonazine, a potent, long-lasting inhibitor of opiate binding sitesLife Sciences, 1982